WebApr 21, 2024 · Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition … WebGilead Sciences Inc: Substituted 6-azabenzimidazole compounds as hpk1 inhibitors WO2024092528A1 (en) 2024-10-31: 2024-05-07: Gilead ... Shenzhen Ionova Life Science Co., Ltd. Pyrimidine and pyridine derivatives as hpk1 modulator and methods using same WO2024100688A1 ...
IONOVA Announces Clinical Trial Collaboration with MSD to …
WebWe would like to show you a description here but the site won’t allow us. WebAug 27, 2024 · SHENZHEN, China, Aug. 27, 2024 /PRNewswire/ -- On August 27, 2024, Shenzhen IONOVA Life Science Co., Ltd. ('IONOVA' or 'the company'), a clinical-... portsmouth tourism
Organization Shenzhen Ionova Life Sciences Co., Ltd.
WebThe applicant listed for this patent is Foshan Ionova Biotherapeutics Co., Inc., Shenzhen Ionova Life Science Co., Ltd.. Invention is credited to Yongkui Sun, Zhaoyin Wang, Gang Zhou. Application Number: 20240352906 16/967130: Document ID / Family ID: 1000005035397: Filed Date: 2024-11-12: View All Diagrams . WebIonova Life Science is a company that operates in the Biotechnology industry. It employs 51-100 people and has $5M-$10M of revenue. The company is headquartered in Shenzhen, … WebApr 29, 2024 · SHENZHEN, China, April 29, 2024 /PRNewswire/ -- Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA's EP4 antagonist, in combination with MSD's anti-PD-1 therapy, KEYTRUDA ® … oracle buyer workbench